These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9617622)

  • 21. [Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years].
    Yamashita A; Hayashi N; Sugimura Y; Yanagawa M; Arima K; Nakano S; Kimbara H; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1995 Jun; 41(6):447-53. PubMed ID: 7645452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of incidental carcinoma of the prostate. II. Nuclear DNA analysis].
    Fujita T; Akino H; Kanimoto Y; Okada K; Shiraishi T; Nakakuki K
    Hinyokika Kiyo; 1991 Sep; 37(9):1009-16. PubMed ID: 1785407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of incidental carcinoma of the prostate. Part 1. Pathological analysis related to the clinical features].
    Fujita T; Kanimoto Y; Akino H; Okada K; Shiraishi T; Nakakuki K
    Hinyokika Kiyo; 1991 Jul; 37(7):695-703. PubMed ID: 1927769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
    Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
    J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Radiotherapy of localized prostatic carcinoma].
    Gez E; Netzer-Horowitz Y; Waiman E; Rubinov R; Cohen Y; Kuten A
    Harefuah; 1997 Dec; 133(12):593-6, 664. PubMed ID: 9451865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens.
    Maru N; Ohori M; Kattan MW; Scardino PT; Wheeler TM
    Hum Pathol; 2001 Aug; 32(8):828-33. PubMed ID: 11521227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
    Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
    Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic criteria in patients with prostate cancer: Gleason score versus volume-weighted mean nuclear volume.
    Fujikawa K; Sasaki M; Arai Y; Yamabe H; Ogawa O; Yoshida O
    Clin Cancer Res; 1997 Apr; 3(4):613-8. PubMed ID: 9815728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical studies of stage D2 prostatic cancer].
    Amano T; Oshinoya Y; Miyazaki K; Fujita Y; Hisazumi H
    Hinyokika Kiyo; 1993 Mar; 39(3):225-9. PubMed ID: 8506794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical studies on the prognostic factors in prostate cancer].
    Horii Y; Yoshida T; Hirai S; Yamauchi T
    Hinyokika Kiyo; 1998 Oct; 44(10):701-5. PubMed ID: 9850833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical study of endocrine therapy in stage B and C prostate cancer].
    Uei T; Okazaki H; Nakamura T; Katou N; Suzuki K; Yamanaka H
    Hinyokika Kiyo; 2003 Nov; 49(11):639-43. PubMed ID: 14719450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.